Obestatin and adropin in Prader-Willi syndrome and non-syndromic obesity: associations with weight, BMI-z, and HOMA-IR

Camila E. Orsso¹, Andrew A. Butler², Michael J. Muehlbauer³, Huaxia N. Cui³, Daniela A. Rubin⁴, Mohammadreza Pakseresht¹, Merlin G. Butler⁵, Carla M. Prado¹, Michael Freemark⁶ and Andrea M. Haqq^{1,7}.

¹Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada; ²Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA; ³Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC, USA; ⁴Dept. of Kinesiology, California State University, Fullerton, CA, USA; ⁵Departments of Psychiatry, Behavioral Sciences, and Pediatrics, Kansas University Medical Center, Kansas city, Kansas, USA; ⁶Division of Pediatric Endocrinology, Duke University Medical Center, Durham, NC, USA; ⁷Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

Corresponding author: Dr. Andrea M. Haqq, Department of Pediatrics, 1C4.09 Walter C. Mackenzie Centre, 8440-112 Street NW, Edmonton, AB T6G 2R7, Canada. Email: <u>haqq@ualberta.ca</u>

Table S1: Obestatin and adropin	n concentrations in childrer	n with Prader-Willi synd	drome according to subty	type and growth hormone treatment.

	PWS subtype			GH treatment			
	UPD (n = 7)	Deletion (n = 13)	P-value [†]	GH treated (n = 9)	non-GH treated (n = 5)	P-value [†]	
Obestatin (pg/mL)	4052.00 (2506.00, 4691.00)	2577.00 (2042.00, 3475.00)	0.30	3339.00 (2933.50, 4062.50)	3331.00 (3099.50, 3766.00)	0.70	
Adropin (ng/mL)	3.90 (2.90, 6.82)	3.53 (2.45, 5.06)	0.42	2.70 (2.07, 6.03)	2.71 (2.23, 3.14)	1.00	

GH, growth hormone; PWS, Prader-Willi syndrome; UPD, uniparental disomy. [†]P-values determined using Mann-Whitney U test.

PWS children with IR (n = 7)	Control children with IR (n = 13)	P-value [†] 0.50	
3472.00 (3146.00, 3764.00)	3505.00 (2978.00, 4194.50)		
2.68 (1.78, 3.43)	2.03 (1.39, 3.10)	0.22	
1266.03 (881.32, 1525.80)	827.66 (706.09, 886.66)	<0.005	
0.34 (0.30, 0.46)	0.20 (0.17, 0.29)	0.01	
40.76 (30.26, 67.34)	37.09 (14.48, 54.91)	0.66	
29.38 (15.91, 36.71)	23.84 (19.39, 36.30)	0.92	
86.00 (78.25, 99.00)	95.50 (87.50, 99.63)	0.18	
5.68 (3.89, 9.27)	5.24 (4.19, 9.22)	0.78	
	(n = 7) 3472.00 (3146.00, 3764.00) 2.68 (1.78, 3.43) 1266.03 (881.32, 1525.80) 0.34 (0.30, 0.46) 40.76 (30.26, 67.34) 29.38 (15.91, 36.71) 86.00 (78.25, 99.00)	(n = 7) $(n = 13)$ $3472.00 (3146.00, 3764.00)$ $3505.00 (2978.00, 4194.50)$ $2.68 (1.78, 3.43)$ $2.03 (1.39, 3.10)$ $1266.03 (881.32, 1525.80)$ $827.66 (706.09, 886.66)$ $0.34 (0.30, 0.46)$ $0.20 (0.17, 0.29)$ $40.76 (30.26, 67.34)$ $37.09 (14.48, 54.91)$ $29.38 (15.91, 36.71)$ $23.84 (19.39, 36.30)$ $86.00 (78.25, 99.00)$ $95.50 (87.50, 99.63)$	

Table S2: Hormonal and metabolic characteristics of children with Prader-Willi syndrome and controls who were insulin resistant.

HOMA-IR, Homeostatic model assessment-insulin resistance; PWS, Prader-Willi syndrome; IR, Insulin resistance.

Data are presented as median (25th percentile, 75th percentile). Statistically significant differences are in bold type ($p \le 0.05$). [†]P-values determined using independent t-test (Pearson).